An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Официальное название

Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients

Обзор

This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels. This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth. To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants. During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors. Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.

Вмешательства

• Препарат Darolutamide (Nubeqa, BAY1841788)
  The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Первичные конечные точки

• Number, severity of adverse events (including SAEs) [Срок оценки: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)]
• Number, severity of adverse drug reactions (including SADRs) [Срок оценки: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)]
• The outcome of (serious) adverse events [Срок оценки: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)]
• The outcome of (serious) adverse drug reactions [Срок оценки: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)]

Вторичные конечные точки (12)

• Metastasis-free survival (MFS) by nmCRPC indication [Срок оценки: Up to 52 weeks]
• Time to first symptomatic skeletal event (SSE) by nmCRPC indication [Срок оценки: Up to 52 weeks]
• Time to prostate-specific antigen (PSA) progression by nmCRPC indication [Срок оценки: Up to 52 weeks]
• Overall survival by nmCRPC indication [Срок оценки: Up to 52 weeks]
• Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication [Срок оценки: Up to 52 weeks]
• Time to first symptomatic skeletal event (SSE) by mHSPC indication [Срок оценки: Up to 52 weeks]
• Time to prostate-specific antigen (PSA) progression by mHSPC indication [Срок оценки: Up to 52 weeks]
• Overall survival by mHSPC indication [Срок оценки: Up to 52 weeks]
• Time to initiation of subsequent anti-cancer therapy by mHSPC indication [Срок оценки: Up to 52 weeks]
• Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication [Срок оценки: Up to 52 weeks]
• Radiological Progression-Free Survival (rPFS) by mHSPC indication [Срок оценки: Up to 52 weeks]
• Duration of Darolutamide treatment [Срок оценки: Up to 52 weeks]

Критерии участия

Критерии включения

• Male aged ≥19 years
• Patients with high risk nmCPRC

• Castrate level of serum testosterone (< 1.7 nmol/l \[50 ng/dL\])
• PSA doubling time < 10 months
• Patients with mHSPC

• histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
• be candidates for androgen-deprivation therapy with/without docetaxel.
• Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice
• Written informed consent from subject or legal representative; assent from subject when appropriate

Критерии исключения

• Patients participating in an investigational program with interventions outside of routine clinical practice
• Participants with contraindication according to the locally approved prescribing information

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

South Korea · 1 центр

• Many locations — Multiple Locations

Идентификаторы

NCT: NCT06334120 · 20654

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗